APO Research
Talk to an analyst

APO RESEARCH · REPORT

Neuroendocrine Tumor Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Neuroendocrine Tumor Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

19 December 2025196 pages

Choose your research edition.

Industry ResearchNeuroendocrine Tumor Drug Industry Research Report 2026133 pages · $2,950 USDIndustry Growth & TrendsGlobal Neuroendocrine Tumor Drug Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Neuroendocrine Tumor Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neuroendocrine Tumor Drug Market Outlook and Growth Opportunities 2026200 pages · $4,250 USDMarket Analysis & ForecastGlobal Neuroendocrine Tumor Drug Market Analysis and Forecast 2026-2032202 pages · $4,950 USD

Market perspective

The global Neuroendocrine Tumor Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Neuroendocrine Tumor Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Neuroendocrine Tumor Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Neuroendocrine Tumor Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Neuroendocrine Tumor Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Neuroendocrine Tumor Drug include Exelixis, Inc., Foresee Pharmaceuticals, LLC, Hutchison MediPharma Limited, Intezyne, Inc, INVENT Pharmaceuticals, Inc., Ipsen S.A., Karyopharm Therapeutics, Inc., Lexicon Pharmaceuticals, Inc. and Midatech Pharma Plc ., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Neuroendocrine Tumor Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Neuroendocrine Tumor Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Neuroendocrine Tumor Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Neuroendocrine Tumor Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Neuroendocrine Tumor Drug Segment by Company

Exelixis, Inc.

Foresee Pharmaceuticals, LLC

Hutchison MediPharma Limited

Intezyne, Inc

INVENT Pharmaceuticals, Inc.

Ipsen S.A.

Karyopharm Therapeutics, Inc.

Lexicon Pharmaceuticals, Inc.

Midatech Pharma Plc .

Millennium Pharmaceuticals, Inc.

MolMed S.p.A.

Northwest Biotherapeutics, Inc.

OctreoPharm Sciences GmbH

OXiGENE, Inc.

Jiangsu Hengrui Medicine Co., Ltd.

Novartis AG

Eisai

Neuroendocrine Tumor Drug Segment by Type

mTOR Protein Inhibitors

Tyrosine Kinase 3 Inhibitors

Growth Hormone Releasing Factor Antagonists

Somatostatin Receptor Agonists

Somatostatin Receptor Antagonists

Others

Neuroendocrine Tumor Drug Segment by Application

Hospital

Clinic

Others

Neuroendocrine Tumor Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neuroendocrine Tumor Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neuroendocrine Tumor Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neuroendocrine Tumor Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Neuroendocrine Tumor Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Neuroendocrine Tumor Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Neuroendocrine Tumor Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Neuroendocrine Tumor Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Neuroendocrine Tumor Drug Industry Trends Table 2. Neuroendocrine Tumor Drug Industry Drivers Table 3. Neuroendocrine Tumor Drug Industry Opportunities and Challenges Table 4. Neuroendocrine Tumor Drug Industry Restraints Table 5. Global Neuroendocrine Tumor Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Neuroendocrine Tumor Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Neuroendocrine Tumor Drug Sales by Manufacturers (W Units) & (2021-2026) Table 8. Global Neuroendocrine Tumor Drug Sales Market Share by Manufacturers Table 9. Global Neuroendocrine Tumor Drug Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Neuroendocrine Tumor Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Neuroendocrine Tumor Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Neuroendocrine Tumor Drug Manufacturers, Product Type & Application Table 13. Global Neuroendocrine Tumor Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Neuroendocrine Tumor Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of mTOR Protein Inhibitors Table 17. Major Manufacturers of Tyrosine Kinase 3 Inhibitors Table 18. Major Manufacturers of Growth Hormone Releasing Factor Antagonists Table 19. Major Manufacturers of Somatostatin Receptor Agonists Table 20. Major Manufacturers of Somatostatin Receptor Antagonists Table 21. Major Manufacturers of Others Table 22. Global Neuroendocrine Tumor Drug Sales by Type 2021 VS 2025 VS 2032 (W Units) Table 23. Global Neuroendocrine Tumor Drug Sales by Type (2021-2026) & (W Units) Table 24. Global Neuroendocrine Tumor Drug Sales by Type (2027-2032) & (W Units) Table 25. Global Neuroendocrine Tumor Drug Sales Market Share by Type (2021-2026) Table 26. Global Neuroendocrine Tumor Drug Sales Market Share by Type (2027-2032) Table 27. Global Neuroendocrine Tumor Drug Revenue by Type 2021 VS 2025 VS 2032 (W Units) Table 28. Global Neuroendocrine Tumor Drug Revenue by Type (2021-2026) & (W Units) Table 29. Global Neuroendocrine Tumor Drug Revenue by Type (2027-2032) & (W Units) Table 30. Global Neuroendocrine Tumor Drug Revenue Market Share by Type (2021-2026) Table 31. Global Neuroendocrine Tumor Drug Revenue Market Share by Type (2027-2032) Table 32. Major Manufacturers of Hospital Table 33. Major Manufacturers of Clinic Table 34. Major Manufacturers of Others Table 35. Global Neuroendocrine Tumor Drug Sales by Application 2021 VS 2025 VS 2032 (W Units) Table 36. Global Neuroendocrine Tumor Drug Sales by Application (2021-2026) & (W Units) Table 37. Global Neuroendocrine Tumor Drug Sales by Application (2027-2032) & (W Units) Table 38. Global Neuroendocrine Tumor Drug Sales Market Share by Application (2021-2026) Table 39. Global Neuroendocrine Tumor Drug Sales Market Share by Application (2027-2032) Table 40. Global Neuroendocrine Tumor Drug Revenue by Application 2021 VS 2025 VS 2032 (W Units) Table 41. Global Neuroendocrine Tumor Drug Revenue by Application (2021-2026) & (W Units) Table 42. Global Neuroendocrine Tumor Drug Revenue by Application (2027-2032) & (W Units) Table 43. Global Neuroendocrine Tumor Drug Revenue Market Share by Application (2021-2026) Table 44. Global Neuroendocrine Tumor Drug Revenue Market Share by Application (2027-2032) Table 45. Global Neuroendocrine Tumor Drug Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 46. Global Neuroendocrine Tumor Drug Sales by Region (2021-2026) & (W Units) Table 47. Global Neuroendocrine Tumor Drug Sales Market Share by Region (2021-2026) Table 48. Global Neuroendocrine Tumor Drug Sales Forecasted by Region (2027-2032) & (W Units) Table 49. Global Neuroendocrine Tumor Drug Sales Forecasted Market Share by Region (2027-2032) Table 50. North America Neuroendocrine Tumor Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 51. North America Neuroendocrine Tumor Drug Sales by Country (2021-2026) & (W Units) Table 52. North America Neuroendocrine Tumor Drug Sales by Country (2027-2032) & (W Units) Table 53. Europe Neuroendocrine Tumor Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 54. Europe Neuroendocrine Tumor Drug Sales by Country (2021-2026) & (W Units) Table 55. Europe Neuroendocrine Tumor Drug Sales by Country (2027-2032) & (W Units) Table 56. Asia Pacific Neuroendocrine Tumor Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 57. Asia Pacific Neuroendocrine Tumor Drug Sales by Country (2021-2026) & (W Units) Table 58. Asia Pacific Neuroendocrine Tumor Drug Sales by Country (2027-2032) & (W Units) Table 59. South America, Middle East and Africa Neuroendocrine Tumor Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 60. South America, Middle East and Africa Neuroendocrine Tumor Drug Sales by Country (2021-2026) & (W Units) Table 61. South America, Middle East and Africa Neuroendocrine Tumor Drug Sales by Country (2027-2032) & (W Units) Table 62. Global Neuroendocrine Tumor Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 63. Global Neuroendocrine Tumor Drug Revenue by Region (2021-2026) & (US$ Million) Table 64. Global Neuroendocrine Tumor Drug Revenue by Region (2027-2032) & (US$ Million) Table 65. Global Neuroendocrine Tumor Drug Revenue Market Share by Region (2021-2026) Table 66. Global Neuroendocrine Tumor Drug Revenue Market Share by Region (2027-2032) Table 67. Exelixis, Inc. Company Information Table 68. Exelixis, Inc. Business Overview Table 69. Exelixis, Inc. Neuroendocrine Tumor Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Exelixis, Inc. Neuroendocrine Tumor Drug Product Portfolio Table 71. Exelixis, Inc. Recent Development Table 72. Foresee Pharmaceuticals, LLC Company Information Table 73. Foresee Pharmaceuticals, LLC Business Overview Table 74. Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Product Portfolio Table 76. Foresee Pharmaceuticals, LLC Recent Development Table 77. Hutchison MediPharma Limited Company Information Table 78. Hutchison MediPharma Limited Business Overview Table 79. Hutchison MediPharma Limited Neuroendocrine Tumor Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Hutchison MediPharma Limited Neuroendocrine Tumor Drug Product Portfolio Table 81. Hutchison MediPharma Limited Recent Development Table 82. Intezyne, Inc Company Information Table 83. Intezyne, Inc Business Overview Table 84. Intezyne, Inc Neuroendocrine Tumor Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Intezyne, Inc Neuroendocrine Tumor Drug Product Portfolio Table 86. Intezyne, Inc Recent Development Table 87. INVENT Pharmaceuticals, Inc. Company Information Table 88. INVENT Pharmaceuticals, Inc. Business Overview Table 89. INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product Portfolio Table 91. INVENT Pharmaceuticals, Inc. Recent Development Table 92. Ipsen S.A. Company Information Table 93. Ipsen S.A. Business Overview Table 94. Ipsen S.A. Neuroendocrine Tumor Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. Ipsen S.A. Neuroendocrine Tumor Drug Product Portfolio Table 96. Ipsen S.A. Recent Development Table 97. Karyopharm Therapeutics, Inc. Company Information Table 98. Karyopharm Therapeutics, Inc. Business Overview Table 99. Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Product Portfolio Table 101. Karyopharm Therapeutics, Inc. Recent Development Table 102. Lexicon Pharmaceuticals, Inc. Company Information Table 103. Lexicon Pharmaceuticals, Inc. Business Overview Table 104. Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 105. Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product Portfolio Table 106. Lexicon Pharmaceuticals, Inc. Recent Development Table 107. Midatech Pharma Plc . Company Information Table 108. Midatech Pharma Plc . Business Overview Table 109. Midatech Pharma Plc . Neuroendocrine Tumor Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 110. Midatech Pharma Plc . Neuroendocrine Tumor Drug Product Portfolio Table 111. Midatech Pharma Plc . Recent Development Table 112. Millennium Pharmaceuticals, Inc. Company Information Table 113. Millennium Pharmaceuticals, Inc. Business Overview Table 114. Millennium Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 115. Millennium Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product Portfolio Table 116. Millennium Pharmaceuticals, Inc. Recent Development Table 117. MolMed S.p.A. Company Information Table 118. MolMed S.p.A. Business Overview Table 119. MolMed S.p.A. Neuroendocrine Tumor Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 120. MolMed S.p.A. Neuroendocrine Tumor Drug Product Portfolio Table 121. MolMed S.p.A. Recent Development Table 122. Northwest Biotherapeutics, Inc. Company Information Table 123. Northwest Biotherapeutics, Inc. Business Overview Table 124. Northwest Biotherapeutics, Inc. Neuroendocrine Tumor Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 125. Northwest Biotherapeutics, Inc. Neuroendocrine Tumor Drug Product Portfolio Table 126. Northwest Biotherapeutics, Inc. Recent Development Table 127. OctreoPharm Sciences GmbH Company Information Table 128. OctreoPharm Sciences GmbH Business Overview Table 129. OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 130. OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Product Portfolio Table 131. OctreoPharm Sciences GmbH Recent Development Table 132. OXiGENE, Inc. Company Information Table 133. OXiGENE, Inc. Business Overview Table 134. OXiGENE, Inc. Neuroendocrine Tumor Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 135. OXiGENE, Inc. Neuroendocrine Tumor Drug Product Portfolio Table 136. OXiGENE, Inc. Recent Development Table 137. Jiangsu Hengrui Medicine Co., Ltd. Company Information Table 138. Jiangsu Hengrui Medicine Co., Ltd. Business Overview Table 139. Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 140. Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Product Portfolio Table 141. Jiangsu Hengrui Medicine Co., Ltd. Recent Development Table 142. Novartis AG Company Information Table 143. Novartis AG Business Overview Table 144. Novartis AG Neuroendocrine Tumor Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 145. Novartis AG Neuroendocrine Tumor Drug Product Portfolio Table 146. Novartis AG Recent Development Table 147. Eisai Company Information Table 148. Eisai Business Overview Table 149. Eisai Neuroendocrine Tumor Drug Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 150. Eisai Neuroendocrine Tumor Drug Product Portfolio Table 151. Eisai Recent Development Table 152. Key Raw Materials Table 153. Raw Materials Key Suppliers Table 154. Neuroendocrine Tumor Drug Distributors List Table 155. Neuroendocrine Tumor Drug Customers List Table 156. Research Programs/Design for This Report Table 157. Authors List of This Report Table 158. Secondary Sources Table 159. Primary Sources List of Figures Figure 1. Neuroendocrine Tumor Drug Product Image Figure 2. Global Neuroendocrine Tumor Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Neuroendocrine Tumor Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Neuroendocrine Tumor Drug Sales (2021-2032) & (W Units) Figure 5. Global Neuroendocrine Tumor Drug Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Neuroendocrine Tumor Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. mTOR Protein Inhibitors Image Figure 9. Tyrosine Kinase 3 Inhibitors Image Figure 10. Growth Hormone Releasing Factor Antagonists Image Figure 11. Somatostatin Receptor Agonists Image Figure 12. Somatostatin Receptor Antagonists Image Figure 13. Others Image Figure 14. Global Neuroendocrine Tumor Drug Sales by Type (2021 VS 2025 VS 2032) & (W Units) Figure 15. Global Neuroendocrine Tumor Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 16. Global Neuroendocrine Tumor Drug Sales Market Share by Type (2021-2032) Figure 17. Global Neuroendocrine Tumor Drug Revenue by Type (2021 VS 2025 VS 2032) & (W Units) Figure 18. Global Neuroendocrine Tumor Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Neuroendocrine Tumor Drug Revenue Market Share by Type (2021-2032) Figure 20. Hospital Image Figure 21. Clinic Image Figure 22. Others Image Figure 23. Global Neuroendocrine Tumor Drug Sales by Application (2021 VS 2025 VS 2032) & (W Units) Figure 24. Global Neuroendocrine Tumor Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 25. Global Neuroendocrine Tumor Drug Sales Market Share by Application (2021-2032) Figure 26. Global Neuroendocrine Tumor Drug Revenue by Application (2021 VS 2025 VS 2032) & (W Units) Figure 27. Global Neuroendocrine Tumor Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 28. Global Neuroendocrine Tumor Drug Revenue Market Share by Application (2021-2032) Figure 29. North America Neuroendocrine Tumor Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 30. North America Neuroendocrine Tumor Drug Sales Market Share by Country (2021-2032) Figure 31. U.S. Neuroendocrine Tumor Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 32. Canada Neuroendocrine Tumor Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 33. Mexico Neuroendocrine Tumor Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 34. Europe Neuroendocrine Tumor Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 35. Europe Neuroendocrine Tumor Drug Sales Market Share by Country (2021-2032) Figure 36. Germany Neuroendocrine Tumor Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 37. France Neuroendocrine Tumor Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 38. U.K. Neuroendocrine Tumor Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 39. Italy Neuroendocrine Tumor Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 40. Netherlands Neuroendocrine Tumor Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 41. Asia Pacific Neuroendocrine Tumor Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 42. Asia Pacific Neuroendocrine Tumor Drug Sales Market Share by Country (2021-2032) Figure 43. China Neuroendocrine Tumor Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 44. Japan Neuroendocrine Tumor Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 45. South Korea Neuroendocrine Tumor Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 46. Southeast Asia Neuroendocrine Tumor Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 47. India Neuroendocrine Tumor Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 48. Australia Neuroendocrine Tumor Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 49. South America, Middle East and Africa Neuroendocrine Tumor Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 50. South America, Middle East and Africa Neuroendocrine Tumor Drug Sales Market Share by Country (2021-2032) Figure 51. Brazil Neuroendocrine Tumor Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 52. South Africa Neuroendocrine Tumor Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 53. Saudi Arabia Neuroendocrine Tumor Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 54. Turkey Neuroendocrine Tumor Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 55. Argentina Neuroendocrine Tumor Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 56. UAE Neuroendocrine Tumor Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 57. Egypt Neuroendocrine Tumor Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 58. Chile Neuroendocrine Tumor Drug Sales and Growth Rate (2021-2032) & (W Units) Figure 59. Global Neuroendocrine Tumor Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Global Neuroendocrine Tumor Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 61. North America Neuroendocrine Tumor Drug Revenue (2021-2032) & (US$ Million) Figure 62. North America Neuroendocrine Tumor Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Europe Neuroendocrine Tumor Drug Revenue (2021-2032) & (US$ Million) Figure 64. Europe Neuroendocrine Tumor Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Asia-Pacific Neuroendocrine Tumor Drug Revenue (2021-2032) & (US$ Million) Figure 66. Asia-Pacific Neuroendocrine Tumor Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. South America, Middle East and Africa Neuroendocrine Tumor Drug Revenue (2021-2032) & (US$ Million) Figure 68. South America, Middle East and Africa Neuroendocrine Tumor Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. Neuroendocrine Tumor Drug Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Neuroendocrine Tumor Drug Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • mTOR Protein Inhibitors
  • Tyrosine Kinase 3 Inhibitors
  • Growth Hormone Releasing Factor Antagonists
  • Somatostatin Receptor Agonists
  • Somatostatin Receptor Antagonists
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Exelixis, Inc.
  • Foresee Pharmaceuticals, LLC
  • Hutchison MediPharma Limited
  • Intezyne, Inc
  • INVENT Pharmaceuticals, Inc.
  • Ipsen S.A.
  • Karyopharm Therapeutics, Inc.
  • Lexicon Pharmaceuticals, Inc.
  • Midatech Pharma Plc .
  • Millennium Pharmaceuticals, Inc.
  • MolMed S.p.A.
  • Northwest Biotherapeutics, Inc.
  • OctreoPharm Sciences GmbH
  • OXiGENE, Inc.
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Novartis AG
  • Eisai

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Neuroendocrine Tumor Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Neuroendocrine Tumor Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Neuroendocrine Tumor Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Neuroendocrine Tumor Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Neuroendocrine Tumor Drug Market Dynamics
  1. 2.1 Neuroendocrine Tumor Drug Industry Trends
  2. 2.2 Neuroendocrine Tumor Drug Industry Drivers
  3. 2.3 Neuroendocrine Tumor Drug Industry Opportunities and Challenges
  4. 2.4 Neuroendocrine Tumor Drug Industry Restraints
3 Neuroendocrine Tumor Drug Market by Manufacturers
  1. 3.1 Global Neuroendocrine Tumor Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Neuroendocrine Tumor Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Neuroendocrine Tumor Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Neuroendocrine Tumor Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Neuroendocrine Tumor Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Neuroendocrine Tumor Drug Manufacturers, Product Type & Application
  7. 3.7 Global Neuroendocrine Tumor Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Neuroendocrine Tumor Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Neuroendocrine Tumor Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Neuroendocrine Tumor Drug Tier 1, Tier 2, and Tier 3
4 Neuroendocrine Tumor Drug Market by Type
  1. 4.1 Neuroendocrine Tumor Drug Type Introduction
  2. 4.1.1 mTOR Protein Inhibitors
  3. 4.1.2 Tyrosine Kinase 3 Inhibitors
  4. 4.1.3 Growth Hormone Releasing Factor Antagonists
  5. 4.1.4 Somatostatin Receptor Agonists
  6. 4.1.5 Somatostatin Receptor Antagonists
  7. 4.1.6 Others
  8. 4.2 Global Neuroendocrine Tumor Drug Sales by Type
  9. 4.2.1 Global Neuroendocrine Tumor Drug Sales by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Neuroendocrine Tumor Drug Sales by Type (2021-2032)
  11. 4.2.3 Global Neuroendocrine Tumor Drug Sales Market Share by Type (2021-2032)
  12. 4.3 Global Neuroendocrine Tumor Drug Revenue by Type
  13. 4.3.1 Global Neuroendocrine Tumor Drug Revenue by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Neuroendocrine Tumor Drug Revenue by Type (2021-2032)
  15. 4.3.3 Global Neuroendocrine Tumor Drug Revenue Market Share by Type (2021-2032)
5 Neuroendocrine Tumor Drug Market by Application
  1. 5.1 Neuroendocrine Tumor Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Neuroendocrine Tumor Drug Sales by Application
  6. 5.2.1 Global Neuroendocrine Tumor Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Neuroendocrine Tumor Drug Sales by Application (2021-2032)
  8. 5.2.3 Global Neuroendocrine Tumor Drug Sales Market Share by Application (2021-2032)
  9. 5.3 Global Neuroendocrine Tumor Drug Revenue by Application
  10. 5.3.1 Global Neuroendocrine Tumor Drug Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Neuroendocrine Tumor Drug Revenue by Application (2021-2032)
  12. 5.3.3 Global Neuroendocrine Tumor Drug Revenue Market Share by Application (2021-2032)
6 Global Neuroendocrine Tumor Drug Sales by Region
  1. 6.1 Global Neuroendocrine Tumor Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Neuroendocrine Tumor Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Neuroendocrine Tumor Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Neuroendocrine Tumor Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Neuroendocrine Tumor Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Neuroendocrine Tumor Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Neuroendocrine Tumor Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Neuroendocrine Tumor Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Neuroendocrine Tumor Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Neuroendocrine Tumor Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Neuroendocrine Tumor Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Neuroendocrine Tumor Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Neuroendocrine Tumor Drug Revenue by Region
  1. 7.1 Global Neuroendocrine Tumor Drug Revenue by Region
  2. 7.1.1 Global Neuroendocrine Tumor Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Neuroendocrine Tumor Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Neuroendocrine Tumor Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Neuroendocrine Tumor Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Neuroendocrine Tumor Drug Revenue (2021-2032)
  8. 7.2.2 North America Neuroendocrine Tumor Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Neuroendocrine Tumor Drug Revenue (2021-2032)
  11. 7.3.2 Europe Neuroendocrine Tumor Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Neuroendocrine Tumor Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Neuroendocrine Tumor Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Neuroendocrine Tumor Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Neuroendocrine Tumor Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Exelixis, Inc.
  2. 8.1.1 Exelixis, Inc. Company Information
  3. 8.1.2 Exelixis, Inc. Business Overview
  4. 8.1.3 Exelixis, Inc. Neuroendocrine Tumor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Exelixis, Inc. Neuroendocrine Tumor Drug Product Portfolio
  6. 8.1.5 Exelixis, Inc. Recent Developments
  7. 8.2 Foresee Pharmaceuticals, LLC
  8. 8.2.1 Foresee Pharmaceuticals, LLC Company Information
  9. 8.2.2 Foresee Pharmaceuticals, LLC Business Overview
  10. 8.2.3 Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Product Portfolio
  12. 8.2.5 Foresee Pharmaceuticals, LLC Recent Developments
  13. 8.3 Hutchison MediPharma Limited
  14. 8.3.1 Hutchison MediPharma Limited Company Information
  15. 8.3.2 Hutchison MediPharma Limited Business Overview
  16. 8.3.3 Hutchison MediPharma Limited Neuroendocrine Tumor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Hutchison MediPharma Limited Neuroendocrine Tumor Drug Product Portfolio
  18. 8.3.5 Hutchison MediPharma Limited Recent Developments
  19. 8.4 Intezyne, Inc
  20. 8.4.1 Intezyne, Inc Company Information
  21. 8.4.2 Intezyne, Inc Business Overview
  22. 8.4.3 Intezyne, Inc Neuroendocrine Tumor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Intezyne, Inc Neuroendocrine Tumor Drug Product Portfolio
  24. 8.4.5 Intezyne, Inc Recent Developments
  25. 8.5 INVENT Pharmaceuticals, Inc.
  26. 8.5.1 INVENT Pharmaceuticals, Inc. Company Information
  27. 8.5.2 INVENT Pharmaceuticals, Inc. Business Overview
  28. 8.5.3 INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product Portfolio
  30. 8.5.5 INVENT Pharmaceuticals, Inc. Recent Developments
  31. 8.6 Ipsen S.A.
  32. 8.6.1 Ipsen S.A. Company Information
  33. 8.6.2 Ipsen S.A. Business Overview
  34. 8.6.3 Ipsen S.A. Neuroendocrine Tumor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Ipsen S.A. Neuroendocrine Tumor Drug Product Portfolio
  36. 8.6.5 Ipsen S.A. Recent Developments
  37. 8.7 Karyopharm Therapeutics, Inc.
  38. 8.7.1 Karyopharm Therapeutics, Inc. Company Information
  39. 8.7.2 Karyopharm Therapeutics, Inc. Business Overview
  40. 8.7.3 Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Product Portfolio
  42. 8.7.5 Karyopharm Therapeutics, Inc. Recent Developments
  43. 8.8 Lexicon Pharmaceuticals, Inc.
  44. 8.8.1 Lexicon Pharmaceuticals, Inc. Company Information
  45. 8.8.2 Lexicon Pharmaceuticals, Inc. Business Overview
  46. 8.8.3 Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product Portfolio
  48. 8.8.5 Lexicon Pharmaceuticals, Inc. Recent Developments
  49. 8.9 Midatech Pharma Plc .
  50. 8.9.1 Midatech Pharma Plc . Company Information
  51. 8.9.2 Midatech Pharma Plc . Business Overview
  52. 8.9.3 Midatech Pharma Plc . Neuroendocrine Tumor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Midatech Pharma Plc . Neuroendocrine Tumor Drug Product Portfolio
  54. 8.9.5 Midatech Pharma Plc . Recent Developments
  55. 8.10 Millennium Pharmaceuticals, Inc.
  56. 8.10.1 Millennium Pharmaceuticals, Inc. Company Information
  57. 8.10.2 Millennium Pharmaceuticals, Inc. Business Overview
  58. 8.10.3 Millennium Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Millennium Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product Portfolio
  60. 8.10.5 Millennium Pharmaceuticals, Inc. Recent Developments
  61. 8.11 MolMed S.p.A.
  62. 8.11.1 MolMed S.p.A. Company Information
  63. 8.11.2 MolMed S.p.A. Business Overview
  64. 8.11.3 MolMed S.p.A. Neuroendocrine Tumor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 MolMed S.p.A. Neuroendocrine Tumor Drug Product Portfolio
  66. 8.11.5 MolMed S.p.A. Recent Developments
  67. 8.12 Northwest Biotherapeutics, Inc.
  68. 8.12.1 Northwest Biotherapeutics, Inc. Company Information
  69. 8.12.2 Northwest Biotherapeutics, Inc. Business Overview
  70. 8.12.3 Northwest Biotherapeutics, Inc. Neuroendocrine Tumor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Northwest Biotherapeutics, Inc. Neuroendocrine Tumor Drug Product Portfolio
  72. 8.12.5 Northwest Biotherapeutics, Inc. Recent Developments
  73. 8.13 OctreoPharm Sciences GmbH
  74. 8.13.1 OctreoPharm Sciences GmbH Company Information
  75. 8.13.2 OctreoPharm Sciences GmbH Business Overview
  76. 8.13.3 OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Product Portfolio
  78. 8.13.5 OctreoPharm Sciences GmbH Recent Developments
  79. 8.14 OXiGENE, Inc.
  80. 8.14.1 OXiGENE, Inc. Company Information
  81. 8.14.2 OXiGENE, Inc. Business Overview
  82. 8.14.3 OXiGENE, Inc. Neuroendocrine Tumor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 OXiGENE, Inc. Neuroendocrine Tumor Drug Product Portfolio
  84. 8.14.5 OXiGENE, Inc. Recent Developments
  85. 8.15 Jiangsu Hengrui Medicine Co., Ltd.
  86. 8.15.1 Jiangsu Hengrui Medicine Co., Ltd. Company Information
  87. 8.15.2 Jiangsu Hengrui Medicine Co., Ltd. Business Overview
  88. 8.15.3 Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Product Portfolio
  90. 8.15.5 Jiangsu Hengrui Medicine Co., Ltd. Recent Developments
  91. 8.16 Novartis AG
  92. 8.16.1 Novartis AG Company Information
  93. 8.16.2 Novartis AG Business Overview
  94. 8.16.3 Novartis AG Neuroendocrine Tumor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Novartis AG Neuroendocrine Tumor Drug Product Portfolio
  96. 8.16.5 Novartis AG Recent Developments
  97. 8.17 Eisai
  98. 8.17.1 Eisai Company Information
  99. 8.17.2 Eisai Business Overview
  100. 8.17.3 Eisai Neuroendocrine Tumor Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Eisai Neuroendocrine Tumor Drug Product Portfolio
  102. 8.17.5 Eisai Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Neuroendocrine Tumor Drug Value Chain Analysis
  2. 9.1.1 Neuroendocrine Tumor Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Neuroendocrine Tumor Drug Production Mode & Process
  6. 9.2 Neuroendocrine Tumor Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Neuroendocrine Tumor Drug Distributors
  9. 9.2.3 Neuroendocrine Tumor Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst